Cardiospondylocarpofacial syndrome is one of the rarest genetic conditions known. Every study, every case report, and every family who shares their story moves the science forward.
Cardiospondylocarpofacial syndrome (CSCF) is caused by heterozygous pathogenic variants in the MAP3K7 gene, which encodes TGF-β-activated kinase 1 (TAK1) — a protein kinase critical to embryonic development and multiple cellular signaling pathways.
Because CSCF is so rare, the medical community has very limited data on its natural history, long-term outcomes, and optimal management. Most clinicians will never encounter a single case in their career. This means families often receive fragmented care from specialists who are unfamiliar with the full picture of the condition.
Every new case report, every family who participates in research, and every clinician who takes an interest in CSCF contributes to a growing body of knowledge that will ultimately improve outcomes for all affected individuals.
If you are a clinician or researcher encountering CSCF for the first time, these are the most important things to understand.
Fewer than 30 cases have been genetically confirmed in medical literature worldwide as of 2025, making CSCF one of the rarest genetic conditions ever described.
CSCF affects the heart, spine, hands, feet, hearing, face, and development simultaneously — requiring coordinated care across multiple medical specialties.
Confirmation of CSCF requires whole exome sequencing (WES) to identify pathogenic variants in the MAP3K7 gene. Clinical features alone are insufficient for diagnosis.
From the first genetic identification in 2016 to the most recent case reports in 2025.
Le Goff et al. published the landmark paper defining CSCF as a distinct genetic syndrome caused by MAP3K7 variants.
Morlino et al. reported CSCF presenting alongside hereditary connective tissue disorder features, expanding the phenotype.
AbuBakr et al. described new features including elbow contractures and wrinkled palms, broadening the clinical spectrum.
Shepherd et al. described the first CSCF case with orofacial clefting, further expanding the known phenotype.
Nyuzuki et al. reported the most severe CSCF case to date, with a variant at the critical TAK1 autophosphorylation site.
Two new papers described dilated cardiomyopathy and previously unreported complications including intestinal obstruction.
These are the areas where new research would have the greatest impact for families living with CSCF.
A global registry of confirmed CSCF cases would enable researchers to identify patterns, track outcomes, and design studies.
Long-term follow-up data is needed to understand how CSCF progresses across the lifespan and which interventions are most effective.
No targeted therapies exist for CSCF. Research into TAK1 pathway modulation could open new treatment avenues.
Understanding why different MAP3K7 variants cause different severity levels is critical for prognosis and counseling.
If you are a geneticist, cardiologist, pediatrician, or researcher with an interest in CSCF or MAP3K7-related conditions, we would love to connect. Your expertise could make a real difference for families navigating this diagnosis.
CSCF Support is a family-led organization. We are not a research institution — but we are deeply committed to connecting families with the researchers and clinicians who can help advance understanding of this condition.
Geneticists & Genetic Counselors
Especially those with experience in MAP3K7-related conditions or rare skeletal dysplasias.
Pediatric Cardiologists
With experience in complex congenital heart disease and rare genetic syndromes.
Pediatricians & Specialists
Any clinician who has encountered or suspects a CSCF diagnosis in a patient.
Researchers
Those interested in TAK1 signaling, rare skeletal conditions, or ultra-rare genetic syndromes.
Patient Advocates
Individuals or organizations working in the rare disease space who want to collaborate.
Direct contact: You can also reach us at hello@cscfsupport.org
Researchers, clinicians, and advocates — we would love to hear from you.